The Lymphoma Channel: Diffuse Large B-Cell Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.

Welcome to The Lymphoma Channel

Diffuse large B-cell Lymphoma (DLBCL) is a malignancy of B-cells and is the most common lymphoid malignancy in adults accounting for 30% of lymphoid malignancies.

It represents a heterogenous group of lymphomas involving the lymph nodes or different extranodal sites. Median age at occurrence is around 70 years despite spanning a broad age range.

Disseminated disease is the most common presentation. The CHOP regimen is the usual standard of care but only induces complete responses in 40-50% of elderly patients and overall survival rates of 30%. Since the introduction of Rituximab, a chimeric anti-CD20IgG1 monoclonal antibody, there has been a significant increase in overall survival. When combined with CHOP, responses have been seen in over 90% of patients.

View Aggressive & Diffuse Large B-Cell Lymphoma Overview Page

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter